# Intestinal Microbiome Modulation With Antibiotics in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer

Source: https://onco.cc/trials/nct06793137/  
OnCo record `nct06793137` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in colorectal cancer, run by AC Camargo Cancer Center, now recruiting.

## Summary

Intestinal Microbiome Modulation With Antibiotics in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer is a phase 2, interventional study registered as NCT06793137 by AC Camargo Cancer Center, with a registry enrolment figure of 100 participants, started 2024-07-22 and due to reach its primary completion in 2025-10-31. Interventions recorded: Metronidazole. Conditions listed: Rectal Cancer, Adenocarcinoma. Primary outcome: Complete clinical response in total neoadjuvant treatment of rectal adenocarcinoma. Colorectal eligibility wording from the registry: "* Patients over 18 years old with middle and lower rectal adenocarcinoma, classified as locally advanced or where the tumor´s location necessitates rectal amputation surgery;". Sites: Brazil. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06793137
- Phase: 2
- Setting: Phase II Trial for Intestinal Microbiome Modulation With Antibiotics in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer
- Sponsor: AC Camargo Cancer Center
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT06793137: https://clinicaltrials.gov/study/NCT06793137

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06793137.json